Price Alert

Rhythm Pharmaceuticals In... (RYTM)

NASDAQ: RYTM · Real-Time Price · USD

96.48

-1.38 (-1.41%)

At close: Aug 14, 2025, 3:59 PM

-1.41% (1D)

Bid	96.12
Market Cap	6.41B
Revenue (ttm)	156.29M
Net Income (ttm)	-183.06M
EPS (ttm)	-3.01
PE Ratio (ttm)	-32.05
Forward PE	-45.66
Analyst	Strong Buy

Ask	98.77
Volume	535,242
Avg. Volume (20D)	712,667
Open	96.86
Previous Close	97.86
Day's Range	95.30 - 97.55
52-Week Range	43.57 - 99.04
Beta	2.39

About RYTM

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol RYTM

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for RYTM stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Rhythm Pharmaceuticals has released their quartely earnings on Aug 5, 2025:

Revenue of $48.5M exceeds estimates by $4.96M, with 66.80% YoY growth.

EPS of -0.75 misses estimates by -0.08, with -36.36% YoY decline.

Next Earnings Release

Rhythm Pharmaceuticals Inc. is scheduled to release its earnings on Nov 4, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

+36.63%

Rhythm Pharmaceuticals shares are trading higher a... Unlock content with Pro Subscription

4 months ago

+5.04%

Rhythm Pharmaceuticals shares are trading higher after multiple analysts raised their price targets on the stock.

News

1 week ago · seekingalpha.com

Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2025 Earnings Call Transcript

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM ) Q2 2025 Earnings Conference Call August 5, 2025 8:00 AM ET Company Participants David Connolly - Head of Investor Relations & Corporate Communications David...

1 week ago · zacks.com

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates

Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to a loss of $0.55 per share a year ago.

2 weeks ago · zacks.com

Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q2 Earnings Expected to Decline

Rhythm Pharmaceuticals (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 weeks ago · fool.com

Rhythm Pharmaceuticals CFO Sells 42,120 Shares

Smith Hunter C, Chief Financial Officer of Rhythm Pharmaceuticals (RYTM -0.04%), reported mixed transactions totaling 42,120 shares on July 9, 2025, as disclosed in an SEC Form 4 filing, resulting in ...

1 month ago · seekingalpha.com

Rhythm: Oral Bivamelagon Data Signals Dominance In Hypothalamic Obesity Market

Rhythm Pharmaceuticals, Inc.'s IMCIVREE and new oral MC4R agonist, bivamelagon, show strong efficacy in rare obesity disorders, especially hypothalamic obesity (HO). HO represents a blockbuster market...

1 month ago · zacks.com

RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data

Rhythm Pharmaceuticals jumps 36.6% after its oral drug bivamelagon shows strong BMI and hunger reductions in a phase II study in acquired hypothalamic obesity.

1 month ago · zacks.com

Rhythm Pharmaceuticals (RYTM) Stock Jumps 36.6%: Will It Continue to Soar?

Rhythm Pharmaceuticals (RYTM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further streng...

1 month ago · investors.com

Rhythm Pharma Surges To Record High On 'Impressive' Results In Obesity

Rhythm Pharmaceuticals shares surged to a record high Wednesday on promising results for a drug that could treat a rare form of obesity.

1 month ago · seekingalpha.com

Rhythm Pharmaceuticals: Rare Genetic Obesity Pioneer With Excellent Prospects

I maintain my Buy rating on Rhythm Pharmaceuticals due to its leadership in rare genetic obesity treatments. The company's innovative therapies address significant unmet needs, supporting long-term gr...

2 months ago · investors.com

Funds Go All In On Weight-Loss Leader; Stock Nears Highs

Rhythm stock is approaching its all-time high in a long base. Rhythm makes drugs to treat disorders due to genetic changes.